Financhill
Sell
11

VKTX Quote, Financials, Valuation and Earnings

Last price:
$34.05
Seasonality move :
24.3%
Day range:
$30.56 - $33.99
52-week range:
$20.92 - $99.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.02x
Volume:
7.6M
Avg. volume:
3.7M
1-year change:
50.99%
Market cap:
$3.7B
Revenue:
--
EPS (TTM):
-$0.93

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VKTX
Viking Therapeutics
-- -$0.27 -- -11.05% $110.00
AMGN
Amgen
$8.9B $5.09 9.65% 258.53% $317.24
LLY
Eli Lilly and
$13.7B $5.28 49.68% 124.93% $977.47
MRK
Merck &
$15.6B $1.76 5.76% -15.62% $125.13
PFE
Pfizer
$17.3B $0.46 27.51% 12.4% $31.18
VRTX
Vertex Pharmaceuticals
$2.8B $4.03 10.63% 10.37% $489.81
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VKTX
Viking Therapeutics
$32.87 $110.00 $3.7B -- $0.00 0% --
AMGN
Amgen
$274.81 $317.24 $147.7B 35.19x $2.25 3.28% 4.56x
LLY
Eli Lilly and
$742.35 $977.47 $704.7B 80.25x $1.30 0.7% 16.43x
MRK
Merck &
$96.24 $125.13 $243.5B 20.18x $0.81 3.24% 3.87x
PFE
Pfizer
$26.64 $31.18 $151B 36.00x $0.42 6.31% 2.55x
VRTX
Vertex Pharmaceuticals
$427.89 $489.81 $110.2B 26.10x $0.00 0% 10.48x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VKTX
Viking Therapeutics
-- 6.065 -- --
AMGN
Amgen
88.92% 0.117 34.87% 0.80x
LLY
Eli Lilly and
68.61% 1.159 3.9% 0.63x
MRK
Merck &
46.15% 0.598 13.95% 0.88x
PFE
Pfizer
41.92% 0.489 40.56% 0.64x
VRTX
Vertex Pharmaceuticals
-- 1.137 -- 2.08x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VKTX
Viking Therapeutics
-- -$36.6M -- -- -- -$22M
AMGN
Amgen
$5.2B $2B 6.14% 65.35% 45.6% $3.3B
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
MRK
Merck &
$12.6B $4B 15.67% 29.26% 26.54% $8.5B
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B
VRTX
Vertex Pharmaceuticals
$2.4B $1.1B -2.89% -2.89% 44.43% $1.3B

Viking Therapeutics vs. Competitors

  • Which has Higher Returns VKTX or AMGN?

    Amgen has a net margin of -- compared to Viking Therapeutics's net margin of 33.28%. Viking Therapeutics's return on equity of -- beat Amgen's return on equity of 65.35%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.22 --
    AMGN
    Amgen
    61.07% $5.22 $67.9B
  • What do Analysts Say About VKTX or AMGN?

    Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 234.65%. On the other hand Amgen has an analysts' consensus of $317.24 which suggests that it could grow by 15.44%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 0 0
    AMGN
    Amgen
    10 14 2
  • Is VKTX or AMGN More Risky?

    Viking Therapeutics has a beta of 0.947, which suggesting that the stock is 5.344% less volatile than S&P 500. In comparison Amgen has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.928%.

  • Which is a Better Dividend Stock VKTX or AMGN?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.28% to investors and pays a quarterly dividend of $2.25 per share. Viking Therapeutics pays -- of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios VKTX or AMGN?

    Viking Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $8.5B. Viking Therapeutics's net income of -$24.9M is lower than Amgen's net income of $2.8B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 35.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 4.56x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$24.9M
    AMGN
    Amgen
    4.56x 35.19x $8.5B $2.8B
  • Which has Higher Returns VKTX or LLY?

    Eli Lilly and has a net margin of -- compared to Viking Therapeutics's net margin of 8.48%. Viking Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.22 --
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About VKTX or LLY?

    Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 234.65%. On the other hand Eli Lilly and has an analysts' consensus of $977.47 which suggests that it could grow by 31.67%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 0 0
    LLY
    Eli Lilly and
    15 6 0
  • Is VKTX or LLY More Risky?

    Viking Therapeutics has a beta of 0.947, which suggesting that the stock is 5.344% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

  • Which is a Better Dividend Stock VKTX or LLY?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.30 per share. Viking Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios VKTX or LLY?

    Viking Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Viking Therapeutics's net income of -$24.9M is lower than Eli Lilly and's net income of $970.3M. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 80.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 16.43x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$24.9M
    LLY
    Eli Lilly and
    16.43x 80.25x $11.4B $970.3M
  • Which has Higher Returns VKTX or MRK?

    Merck & has a net margin of -- compared to Viking Therapeutics's net margin of 18.95%. Viking Therapeutics's return on equity of -- beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.22 --
    MRK
    Merck &
    75.51% $1.24 $82.7B
  • What do Analysts Say About VKTX or MRK?

    Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 234.65%. On the other hand Merck & has an analysts' consensus of $125.13 which suggests that it could grow by 30.02%. Given that Viking Therapeutics has higher upside potential than Merck &, analysts believe Viking Therapeutics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 0 0
    MRK
    Merck &
    14 7 0
  • Is VKTX or MRK More Risky?

    Viking Therapeutics has a beta of 0.947, which suggesting that the stock is 5.344% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

  • Which is a Better Dividend Stock VKTX or MRK?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.24% to investors and pays a quarterly dividend of $0.81 per share. Viking Therapeutics pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or MRK?

    Viking Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Viking Therapeutics's net income of -$24.9M is lower than Merck &'s net income of $3.2B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 3.87x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$24.9M
    MRK
    Merck &
    3.87x 20.18x $16.7B $3.2B
  • Which has Higher Returns VKTX or PFE?

    Pfizer has a net margin of -- compared to Viking Therapeutics's net margin of 25.23%. Viking Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.22 --
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About VKTX or PFE?

    Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 234.65%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 17.02%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 0 0
    PFE
    Pfizer
    7 13 1
  • Is VKTX or PFE More Risky?

    Viking Therapeutics has a beta of 0.947, which suggesting that the stock is 5.344% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

  • Which is a Better Dividend Stock VKTX or PFE?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.31% to investors and pays a quarterly dividend of $0.42 per share. Viking Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or PFE?

    Viking Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Viking Therapeutics's net income of -$24.9M is lower than Pfizer's net income of $4.5B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$24.9M
    PFE
    Pfizer
    2.55x 36.00x $17.7B $4.5B
  • Which has Higher Returns VKTX or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to Viking Therapeutics's net margin of 37.71%. Viking Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    VKTX
    Viking Therapeutics
    -- -$0.22 --
    VRTX
    Vertex Pharmaceuticals
    85.84% $4.01 $15.6B
  • What do Analysts Say About VKTX or VRTX?

    Viking Therapeutics has a consensus price target of $110.00, signalling upside risk potential of 234.65%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 14.47%. Given that Viking Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VKTX
    Viking Therapeutics
    9 0 0
    VRTX
    Vertex Pharmaceuticals
    17 10 2
  • Is VKTX or VRTX More Risky?

    Viking Therapeutics has a beta of 0.947, which suggesting that the stock is 5.344% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

  • Which is a Better Dividend Stock VKTX or VRTX?

    Viking Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VKTX or VRTX?

    Viking Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Viking Therapeutics's net income of -$24.9M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Viking Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics is -- versus 10.48x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VKTX
    Viking Therapeutics
    -- -- -- -$24.9M
    VRTX
    Vertex Pharmaceuticals
    10.48x 26.10x $2.8B $1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Philip Morris Stock Overvalued?
Is Philip Morris Stock Overvalued?

If there is one industry that can be termed truly…

What Quantum Stocks Should I Buy?
What Quantum Stocks Should I Buy?

The last several years have seen a series of tech…

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
32
FTAI alert for Jan 22

FTAI Aviation [FTAI] is up 9.81% over the past day.

Sell
2
EDU alert for Jan 22

New Oriental Education & Technology Group [EDU] is down 1.13% over the past day.

Buy
51
GH alert for Jan 22

Guardant Health [GH] is up 4.5% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock